In particular, the latest diabetes treatment guidelines emphasize the usefulness of SGLT2, but it is only an evaluation based on the additional effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers [26]. This evidence concerns the gene ACE and diabetes mellitus.